Mumbai, India, June 20, 2020: Piramal Enterprises Limited’s (PEL) Pharma Solutions business, a leading
Contract Development and Manufacturing Organization (CDMO), today announced that the Company
has entered into an agreement with G&W Laboratories Inc. to acquire its solid oral dosage drug product
manufacturing facility located in Sellersville, Pennsylvania. The transaction closure is subject to
customary pre-closing conditions. According to the terms of the agreement, PEL, through one of its
Affiliates, would acquire at closing a 100% stake in the entity that operates the facility and owns the
related real estate.
This acquisition broadens the offering of Piramal Pharma Solutions (PPS) by adding solid oral dosage
form capabilities (tablets and capsules) in North America. Until now, PPS’ capabilities in solid oral dosage
forms were all located in the UK and India. The Sellersville site can also produce liquids, creams, and
ointments, further expanding the PPS portfolio. The site also can support product and process
development for solid oral dosage and oral liquids, including immediate release, modified release,
chewable & sublingual solid oral dosage forms, solutions and suspensions in liquids. The site has received
certifications from the FDA and EMA.
“Many of our customers are looking for US-based manufacturing partners to expand and support their
pipeline. This acquisition strengthens our ability to partner with them on best-in-class drug products. It
enhances our market-leading integrated services offering by adding a solid oral dosage capability in the
US. We now offer solid oral drug product development and commercial manufacturing in all our major
geographies, addressing a previously unmet customer need and strengthening our ability to work
globally with customers to reduce the burden of disease on patients,” said Peter DeYoung, Chief
Executive Officer, Piramal Pharma Solutions.
The Sellersville site covers 31.5 acres of land with over 221,000 square feet of manufacturing space,
including 195,000 square feet of GMP area. The site features dedicated manufacturing and packaging
technologies for solid oral dosage forms, liquids, creams, and ointments; QC and microbiology labs;
state-of-the-art preformulation and analytical development infrastructure coupled with a pilot lab for
research and development; and a temperature-controlled warehouse. The site currently has the
necessary controls to support manufacturing of potent solid oral dosage forms. PPS intends to offer high
potency drug manufacturing capabilities at the site, complementing the Company’s global strength in
highly potent compounds. The site employs a highly knowledgeable and experienced workforce of ~100,
with an average of 19 years of service with the site. PPS expects to further grow the site’s current
strength to support development services as well as any COVID-19 management drug opportunities.
Expanding the PPS service offerings directly supports the Company’s philosophy of Patient Centricity.
Understanding the needs of patients and building an organization that is dedicated to addressing those
needs is the foundation of Patient Centricity. By putting patients first, PPS is aligning its mission with that
of its customers, becoming better partners who share a common goal.
***
About Piramal Pharma Solutions:
Piramal Pharma Solutions is a contract development and manufacturing organization (CDMO), offering
end-to-end development and manufacturing solutions across the drug life cycle. We serve our clients
through a globally integrated network of facilities in North America, Europe and Asia. This enables us to
offer a comprehensive range of services including Drug Discovery Solutions, Process & Pharmaceutical
Development services, Clinical Trial Supplies, Commercial supply of APIs and Finished dosage forms. We
also offer specialized services like development and manufacture of Highly Potent APIs and Antibody
Drug Conjugation. Our capability as an integrated service provider & experience with various
technologies enables us to serve Innovator and Generic companies worldwide. For more information
and updates, please visit: www.piramalpharmasolutions.com | Social Media: Twitter, LinkedIn
About Piramal Enterprises Limited:
Piramal Enterprises Limited (PEL) is one of India’s large diversified companies, with presence in Financial
Services and Pharmaceuticals. PEL’s consolidated revenues were ~US$1.7 billion in FY2020, with ~34%
of revenues generated from outside India.
In Financial Services, PEL offers a complete suite of financial products in both wholesale and retail
financing across sectors. The Group has long-standing partnerships with leading institutional investors
such as CPPIB, APG, Ivanhoé Cambridge (subsidiary of CDPQ) and Bain Capital Credit. PEL also has equity
investments in the Shriram Group, a leading financial conglomerate in India.
In Pharma, through end-to-end manufacturing capabilities across 13 global facilities and a large global
distribution network to over 100 countries, PEL sells a portfolio of niche differentiated pharma products
and provides an entire pool of pharma services (including in the areas of injectable, HPAPI etc.).
The Company is also strengthening its presence in the Consumer Product segment in India.
PEL is listed on the BSE Limited and the National Stock Exchange of India Limited in India. For more
information and updates, please visit: www.piramal.com | Social Media: Facebook, Twitter, LinkedIn
For Queries, please reach out to:
Investor Relations Media
Hitesh Dhaddha | Sarang Nakadi
Contact: +91 22 3046 6306 | 6416
investor.relations@piramal.com
Dimple Kapur | Riddhi Goradia
Contact: +91 22 3046 6403 | 6307
dimple.kapur@piramal.com
riddhi.goradia@piramal.com
